Table of Contents

company-logo

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

LAVA Therapeutics Dividend Announcement

• LAVA Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on LAVA Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

LAVA Therapeutics Dividend History

LAVA Therapeutics Dividend Yield

LAVA Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing LAVA Therapeutics stock? Use our calculator to estimate your expected dividend yield:

LAVA Therapeutics Financial Ratios

P/E ratio-2.12
PEG ratio0.02
P/B ratio1.19
ROE-48.53%
Payout ratio0.00%
Current ratio6.39
Quick ratio6.39
Cash Ratio2.49

LAVA Therapeutics Dividend FAQ

Does LAVA Therapeutics stock pay dividends?
LAVA Therapeutics does not currently pay dividends to its shareholders.
Has LAVA Therapeutics ever paid a dividend?
No, LAVA Therapeutics has no a history of paying dividends to its shareholders. LAVA Therapeutics is not known for its dividend payments.
Why doesn't LAVA Therapeutics pay dividends?
There are several potential reasons why LAVA Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will LAVA Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While LAVA Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is LAVA Therapeutics a dividend aristocrat?
LAVA Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is LAVA Therapeutics a dividend king?
LAVA Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is LAVA Therapeutics a dividend stock?
No, LAVA Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy LAVA Therapeutics stocks?
To buy LAVA Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy LAVA Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.